Didanosine, Lamivudine, Nevirapine — Competitive Intelligence Brief

Didanosine, Lamivudine, Nevirapine (Didanosine, Lamivudine, Nevirapine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination (NRTI + NNRTI). Area: Infectious Disease / Virology.

phase 3 Antiretroviral combination (NRTI + NNRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Didanosine, Lamivudine, Nevirapine (Didanosine, Lamivudine, Nevirapine) — Tuberculosis Research Centre, India. This is a fixed-dose combination of three nucleoside/non-nucleoside reverse transcriptase inhibitors that block HIV replication by inhibiting the enzyme responsible for converting viral RNA into DNA.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Didanosine, Lamivudine, Nevirapine TARGET	Didanosine, Lamivudine, Nevirapine	Tuberculosis Research Centre, India	phase 3	Antiretroviral combination (NRTI + NNRTI)	HIV reverse transcriptase
Abacavir sulfate, Lamivudine and Zidovudine	Abacavir sulfate, Lamivudine and Zidovudine	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
Atazanavir + 2 NRTIs	Atazanavir + 2 NRTIs	Bristol-Myers Squibb	marketed	Protease inhibitor (PI) + nucleoside reverse transcriptase inhibitors (NRTIs)	HIV protease; HIV reverse transcriptase
Twice-daily ABC+3TC	Twice-daily ABC+3TC	Medical Research Council	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
Sofosbuvir, Ribavirin, and Stribild	Sofosbuvir, Ribavirin, and Stribild	Saint Michael's Medical Center	marketed	Direct-acting antiviral (DAA) combination; antiretroviral combination	HCV NS5B RNA polymerase; HIV integrase; HIV reverse transcriptase
TDF/3TC/EFV or DTG or NVP	TDF/3TC/EFV or DTG or NVP	MU-JHU CARE	marketed	Antiretroviral combination therapy (NRTI + NNRTI or INSTI)	HIV reverse transcriptase, HIV integrase
TRUVADA + Raltegravir	TRUVADA + Raltegravir	Fenway Community Health	marketed	Antiretroviral combination therapy (NRTI + INSTI)	HIV reverse transcriptase and HIV integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination (NRTI + NNRTI) class)

1. Sheba Medical Center · 1 drug in this class
2. Tuberculosis Research Centre, India · 1 drug in this class